Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
207 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Rank Status Study
21 Recruiting Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib
22 Recruiting Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)
Conditions: Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis
Intervention: Drug: Eltrombopag
23 Recruiting Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
24 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
25 Recruiting Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Chronic Phase;   Adults
Intervention: Drug: Ponatinib
26 Recruiting A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Omacetaxine mepesuccinate
27 Unknown  Pediatric Chronic Myeloid Leukemia Registry
Condition: Chronic Myeloid Leukemia
Intervention:
28 Not yet recruiting Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: blood sampling
29 Recruiting Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: Nilotinib
30 Recruiting Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)
Condition: Chronic Myeloid Leukemia
Intervention: Other: biological samples
31 Not yet recruiting Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib
32 Recruiting Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Zileuton (Zyflo®) Dasatinib (Sprycel®);   Drug: Dosing with Zileuton/Dasatinib in CML;   Drug: Daily dosing of Zileuton/Dasatinib;   Drug: Daily dosing with Zileuton/Dasatinib for CML
33 Recruiting Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib
34 Recruiting Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Peginterferon α2b;   Drug: Nilotinib
35 Recruiting Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
36 Recruiting A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Nivolumab
37 Unknown  Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)
Condition: Chronic Myeloid Leukemia or Ph Positive ALL
Intervention:
38 Recruiting Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Imatinib;   Drug: Dasatinib
39 Recruiting Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
40 Recruiting Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Arsenic trioxide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years